BioNTech SE (NASDAQ:BNTX – Get Free Report) saw unusually-high trading volume on Monday after Bank of America raised their price target on the stock from $125.00 to $150.00. Bank of America currently has a buy rating on the stock. Approximately 676,574 shares were traded during trading, a decline of 9% from the previous session’s volume of 746,643 shares.The stock last traded at $123.20 and had previously closed at $123.40.
A number of other brokerages have also recently weighed in on BNTX. HC Wainwright reissued a “buy” rating and issued a $113.00 price target on shares of BioNTech in a research report on Monday. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. HSBC raised shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and boosted their price target for the company from $91.00 to $125.00 in a research report on Monday. Finally, TD Cowen reduced their price target on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $113.85.
Institutional Inflows and Outflows
BioNTech Trading Up 0.1 %
The stock has a market cap of $29.35 billion, a PE ratio of 246.94 and a beta of 0.23. The business’s fifty day moving average is $88.13 and its 200 day moving average is $89.90. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.
BioNTech (NASDAQ:BNTX – Get Free Report) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The company had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm’s quarterly revenue was down 23.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.86) EPS. As a group, analysts predict that BioNTech SE will post -2.8 earnings per share for the current year.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
See Also
- Five stocks we like better than BioNTech
- Consumer Staples Stocks, Explained
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- What is the Dogs of the Dow Strategy? Overview and Examples
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.